Only in Titles

Search results for: Recombinant Human Vascular Endothelial Growth Factor rh-VEGF165

paperclip

Error loading info... Pleas try again later.
paperclip

#31541344   2019/09/20 To Up

Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms.

Recombinant human vascular endothelial growth factor (rhVEGF) has important applications in therapeutic angiogenesis and inhibition of VEGF-mediated pathological angiogenesis. Previous studies have shown that rhVEGF can be produced in several expression systems, including Escherichia coli, yeasts, insect cells and mammalian cells. However, little is known regarding the effective production of this protein in organs of live organisms. Here, we report for the first time the expression and characterization of rhVEGF165 in the middle silk gland (MSG) of the transgenic silkworm line S1-V165. Our results confirmed that (1) rhVEGF165 was highly expressed in MSG cells and was secreted into the cocoon of S1-V165; (2) the dimeric form of rhVEGF165 could be easily dissolved from S1-V165 cocoons using an alkaline solution; (3) rhVEGF165 extracted from S1-V165 cocoons exhibited slightly better cell proliferative activity than the hVEGF165 standard in cultured human umbilical vein endothelial cells. This study provides an alternative strategy for the production of bioactive rhVEGF165 using the MSG of transgenic silkworms.
Tianyang Zhang, Rongpeng Liu, Qin Luo, Dawei Qu, Tao Chen, Ou Yao, Hanfu Xu

2664 related Products with: Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms.

2 10 mg2020 10 100 2 1 mg2 25 50 10

Related Pathways

paperclip

#29614715   2018/03/31 To Up

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization.

Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring antibodies that can be isolated from naïve, immune or synthetic shark libraries. These molecules are very interesting to the biotechnology and pharmaceutical industries because of their unique characteristics related to size and tissue penetrability. There have been some approved anti-angiogenic therapies for ophthalmic conditions, not related to vNAR. This includes biologics and chimeric proteins that neutralize vascular endothelial growth factor (VEGF), which are injected intravitreal, causing discomfort and increasing the possibility of infection. In this paper, we present a vNAR antibody against human recombinant VEGF (rhVEGF) that was isolated from an immunized shark. A vNAR called V13, neutralizes VEGF cytokine starting at 75 μg/mL in an in vitro assay based on co-culture of normal human dermal fibroblasts (NHDFs) and green fluorescence protein (GFP)-labeled human umbilical vein endothelial cells (HUVECs) cells. In the oxygen-induced retinopathy model in C57BL/6:Hsd mice, we demonstrate an endothelial cell count decrease. Further, we demonstrate the intraocular penetration after topical administration of 0.1 μg/mL of vNAR V13 by its detection in aqueous humor in New Zealand rabbits with healthy eyes after 3 h of application. These findings demonstrate the potential of topical application of vNAR V13 as a possible new drug candidate for vascular eye diseases.
Tanya A Camacho-Villegas, María Teresa Mata-González, Walter García-Ubbelohd, Linda Núñez-García, Carolina Elosua, Jorge F Paniagua-Solis, Alexei F Licea-Navarro

2874 related Products with: Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization.

48 samples1 Set50 ug96 tests1 Set1 Set100ug

Related Pathways

paperclip

#29468155   2018/02/05 To Up

A Low Cost Implantation Model in the Rat That Allows a Spatial Assessment of Angiogenesis.

There is continual demand for animal models that allow a quantitative assessment of angiogenic properties of biomaterials, therapies, and pharmaceuticals. In its simplest form, this is done by subcutaneous material implantation and subsequent vessel counting which usually omits spatial data. We have refined an implantation model and paired it with a computational analytic routine which outputs not only vessel count but also vessel density, distribution, and vessel penetration depth, that relies on a centric vessel as a reference point. We have successfully validated our model by characterizing the angiogenic potential of a fibrin matrix in conjunction with recombinant human vascular endothelial growth factor (rhVEGF165). The inferior epigastric vascular pedicles of rats were sheathed with silicone tubes, which were subsequently filled with 0.2 ml of fibrin and different doses of rhVEGF165, centrically embedding the vessels. Over 4 weeks, tissue samples were harvested and subsequently immunohistologically stained and computationally analyzed. The model was able to detect variations over the angiogenic potentials of growth factor spiked fibrin matrices. Adding 20 ng of rhVEGF165 resulted in a significant increase in vasculature while 200 ng of rhVEGF165 did not improve vascular growth. Vascularized tissue volume increased during the first week and vascular density increased during the second week. Total vessel count increased significantly and exhibited a peak after 2 weeks which was followed by a resorption of vasculature by week 4. In summary, a simple implantation model to study vascularization with only a minimal workload attached was enhanced to include morphologic data of the emerging vascular tree.
Paul Slezak, Cyrill Slezak, Joachim Hartinger, Andreas Herbert Teuschl, Sylvia Nürnberger, Heinz Redl, Rainer Mittermayr

1545 related Products with: A Low Cost Implantation Model in the Rat That Allows a Spatial Assessment of Angiogenesis.

50ug48 samples4 Membranes/Box14 Membranes/Box4 Arrays/Slide4 Arrays/Slide

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#28453232   2017/07/07 To Up

Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.

To test the hypothesis that the addition of small amounts of rhVEGF to rhBMP2 in a polymer carrier can accomplish equivalent repair effect as a reduced dosage of rhBMP2 compared to rhBMP2 alone.
Markus Tröltzsch, Alexander Klenke, Petra Santander, Philipp Kauffmann, Matthias Tröltzsch, Anna Rau, Phillip Brockmeyer, Henning Schliephake

2908 related Products with: Repair of large saddle defects of the mandibular ridge using dual growth factor release-An experimental pilot study in minipigs.

100.00 ug100.00 ug4 Membranes/Box100 μg100.00 ug2 Pieces/Box100.00 ug0.1ml (1mg/ml)100.00 ug100.00 ugProtein

Related Pathways

paperclip

#27663536   2016/08/27 To Up

The Use of Sequential VEGF- and BMP2-Releasing Biodegradable Scaffolds in Rabbit Mandibular Defects.

Promising developments have materialized in reconstructive surgical procedures with the applications of tissue engineering. In our study, we used tissue scaffolds fabricated from polylactic acid-polyethylene glycol (PLLA-PEG) copolymers to ensure different release rates of selective growth factors recombinant human bone morphogenetic protein 2 [rhBMP-2] and vascular endothelial growth factor (rhVEGF165) in the repair of mandibular bone defects.
Nilüfer Çakır-Özkan, Sinan Eğri, Esengül Bekar, B Zuhal Altunkaynak, Yonca Betil Kabak, Elfide Gizem Kıvrak

1463 related Products with: The Use of Sequential VEGF- and BMP2-Releasing Biodegradable Scaffolds in Rabbit Mandibular Defects.

100ug100ug100ug Lyophilized100 100ug100ug Lyophilized100ug Lyophilized100ug Lyophilized50ul100ug100ug100ug Lyophilized

Related Pathways

paperclip

#26485046   2015/10/17 To Up

Continuous delivery of rhBMP2 and rhVEGF165 at a certain ratio enhances bone formation in mandibular defects over the delivery of rhBMP2 alone--An experimental study in rats.

The aim of the present study was to test the hypothesis that different amounts of vascular endothelial growth factor and bone morphogenic protein differentially affect bone formation when applied for repair of non-healing defects in the rat mandible. Porous composite PDLLA/CaCO3 carriers were fabricated as slow release carriers and loaded with rhBMP2 and rhVEGF165 in 10 different dosage combinations using gas foaming with supercritical carbon dioxide. They were implanted in non-healing defects of the mandibles of 132 adult Wistar rats with additional lateral augmentation. Bone formation was assessed both radiographically (bone volume) and by histomorphometry (bone density). The use of carriers with a ratio of delivery of VEGF/BMP between 0.7 and 1.2 was significantly related to the occurrence of significant increases in radiographic bone volume and/or histologic bone density compared to the use of carriers with a ratio of delivery of ≤ 0.5 when all intervals and all outcome parameters were considered. Moreover, simultaneous delivery at this ratio helped to "save" rhBMP2 as both bone volume and bone density after 13 weeks were reached/surpassed using half the dosage required for rhBMP2 alone. It is concluded, that the combined delivery of rhVEGF165 and rhBMP2 for repair of critical size mandibular defects can significantly enhance volume and density of bone formation over delivery of rhBMP2 alone. It appears from the present results that continuous simultaneous delivery of rhVEGF165 and rhBMP2 at a ratio of approximately 1 is favourable for the enhancement of bone formation.
N Lohse, N Moser, S Backhaus, T Annen, M Epple, H Schliephake

1062 related Products with: Continuous delivery of rhBMP2 and rhVEGF165 at a certain ratio enhances bone formation in mandibular defects over the delivery of rhBMP2 alone--An experimental study in rats.

100 μg1 Set1 Set100 μg100 μg100 μg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#25607471   2015/01/20 To Up

Recombinant human vascular endothelial growth factor receptor 1 effectively inhibits angiogenesis in vivo.

Vascular endothelial growth factor (VEGF) plays an important role in both physiological and pathological angiogenesis. VEGF receptor‑1 (VEGFR‑1) acts as a decoy VEGF receptor that enables the regulation of VEGF on the vascular endothelium. In the present study, the recombinant human VEGFR1D1‑3/Fc (rhVEGFR‑1), which contains key domains for VEGF binding, was cloned and expressed in Chinese hamster ovary (CHO) cells. The rhVEGFR‑1 protein was purified using protein‑A affinity chromatography. The molecular weight of rhVEGFR‑1 was found to be ~162 and 81 kD in non‑reducing and reducing SDS‑PAGE, respectively. The majority of the final protein products were in the dimeric conformation. Western blot analysis revealed that rhVEGFR‑1 was only capable of binding to the full glycan form of rhVEGF‑165 and rhVEGF‑121. The dissociation constant for the binding of rhVEGFR‑1 to VEGF‑165, detected using Biacore, was 285 pM. In addition, rhVEGFR‑1 inhibited the proliferation and migration of human microvascular endothelial cells. In vivo experiments also demonstrated that rhVEGFR‑1 inhibited chicken chorioallantoic membrane neovascularization and angiogenesis in nude mice. In conclusion, an anti‑angiogenic recombinant soluble VEGFR was expressed (up to 5 mg/l) in CHO cells and was shown to be capable of inhibiting neovascularization in vivo and in vitro.
Jinliang Wang, Minglei Shi, Yongyi Xi, Lihua Gao, Guanyi Zhang, Yong Shao, Huipeng Chen, Xianwen Hu

1406 related Products with: Recombinant human vascular endothelial growth factor receptor 1 effectively inhibits angiogenesis in vivo.

2ug x 202ug2ug20 ug10ug5ug10 ug10ug50 ug10ug100ul 100ul

Related Pathways